Fundamental & clinical pharmacology
-
Fundam Clin Pharmacol · Aug 2009
Underlying mechanism of penehyclidine hydrochloride on isolated rat uterus.
We investigated the underlying mechanisms of penehyclidine hydrochloride (PHC), a novel selective anticholinergic drug on isolated rat uterus. The method of radio-immunity assay was further employed to determine cyclic adenosine mono phosphate (cAMP) levels in isolated rat uterus for comparing with selective effect on muscarinic receptor subtypes. In the assay, PHC could decrease the content of cAMP in isolated rat uterus, but the difference was not statistically significant at dose of 10 mumol/L. In conclusion, our results suggested that PHC has no or poor effect on M(2) receptor subtypes in isolated rat uterus.
-
Fundam Clin Pharmacol · Jun 2009
Historical ArticleMedicines submitted to narcotics regulations in France, 1992-2007.
The objective was to study the current narcotics regulations which are the most restrictive regarding prescription and dispensation practice in France, and their evolution over the period 1992-2007. This is an example of regulation in a European member state regarding medicines with a risk of abuse or dependence. Narcotics regulations were studied in the French public health code. ⋯ The prescription rules could be different for a given substance according to the route of administration or indication. In 2007, half of the narcotic opioids could be prescribed for 28 days, whereas in 1992, most of them could be prescribed for only 7 days. These results show the adaptation of French narcotics regulations, with the development of medicines indicated in acute or chronic pain treatment or opioid maintenance treatment.
-
Fundam Clin Pharmacol · Jun 2009
Abstracts of the 13th Annual Meeting of the French Society of Pharmacology and Therapeutics, the 76th Annual Meeting of Society of Physiology, the 30th Pharmacovigilance Meeting, the 10th APNET Seminar, and the 7th CHU CIC Meeting. April 15-17, 2009. Marseille, France.
-
Fundam Clin Pharmacol · Apr 2009
Dextropropoxyphene withdrawal from a French university hospital: impact on analgesic drug consumption.
Dextropropoxyphene is a weak opioid analgesic, widely used as a step 2 analgesic (according to WHO classification) in combination with peripheral analgesics, mainly paracetamol. Recent data have underlined its poor analgesic efficacy (in comparison with paracetamol), risks of serious adverse drug reactions (i.e. hepatic reactions, hallucinations, abuse, withdrawal symptoms, hypoglycaemia), possible lethality after overdose, its risk of accumulation in patients with renal failure or in elderly people and some pharmacokinetic insufficiencies (i.e. different half-lives for dextropropoxyphene and paracetamol). Taking into account these data, the drug committee of the Toulouse University Hospital (France) decided to withdraw dextropropoxyphene from the hospital formulary since 1 June 2005. ⋯ These results show that dextropropoxyphene withdrawal was not associated with a marked switch in prescriptions towards other analgesic drugs. This paper underlines the interest of a hospital-based drug committee to promote rational drug use. Finally, the present data allow us to discuss putative misuse of dextropropoxyphene.
-
Fundam Clin Pharmacol · Feb 2009
Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid.
A pharmacokinetic-pharmacodynamic (PK-PD) drug-drug interaction between acenocoumarol and amoxicillin + clavulanic acid antibiotic was assessed in eight healthy volunteers, using a population PK-PD) model. Each subject received at day 1 a single dose of 8 mg of acenocoumarol. Then 1 g of amoxicillin + 250 mg of clavulanic acid was given from days 3 to 9. ⋯ An indirect response model was successfully applied to the PK-PD data of acenocoumarol. No covariate, including antibiotic treatment effect, significantly affected PT. Drug-drug interaction was demonstrated at the PK level, without any PD corollary.